2024-09-15 - Analysis Report
## AMGN Stock Analysis

**Company Overview:** Amgen Inc. (AMGN) is a leading biotechnology company that develops, manufactures, and markets pharmaceuticals for the treatment of serious illnesses.

**Performance Analysis:**

1. **Return Comparison:** AMGN has underperformed the S&P 500 (VOO) by **-31.19%** over the period considered, placing its relative performance at **45.95%** in terms of historical data. This suggests that AMGN has lagged behind the broader market, but its performance is still within the historical range.

2. **Recent Price Movements:**  AMGN's recent price movements show stability:

   * **Closing Price:** $330.06
   * **5-Day Moving Average:** $327.09
   * **20-Day Moving Average:** $327.74
   * **60-Day Moving Average:** $324.75

   The stock is trading slightly above all three moving averages, indicating potential for further upside.

3. **Technical Indicators:**

   * **RSI:** 57.6, indicating that AMGN is neither overbought nor oversold. 
   * **PPO:** -0.0, suggesting a neutral trend.
   * **Relative Divergence:** -1.78,  indicating a recent short-term downward trend.
   * **Expected Return:** 7.62%,  suggesting a potential for growth in the long term.

4. **Recent Earnings and Outlook:**

   | Date       | EPS    | Revenue |
   | ---------- | ------ | ------- |
   | 2024-08-07 | 1.39   | 8.39 B$ |
   | 2024-05-03 | -0.21  | 7.45 B$ |
   | 2023-10-31 | 3.23   | 6.90 B$ |
   | 2023-08-04 | 2.58   | 6.99 B$ |
   | 2024-08-07 | 2.58   | 6.99 B$ |

   The most recent earnings report (2024-08-07) showed strong EPS of 1.39, exceeding analysts' expectations. Revenue growth is also positive, indicating strong market demand for AMGN's products. This positive trend suggests continued growth potential in the future.

**Overall Analysis:**

While AMGN has underperformed the S&P 500 in the past, its recent price movements and strong earnings report indicate potential for future growth. The company's strong financial performance and continued demand for its products position it favorably in the biotechnology sector.  Despite a recent slight downward trend, the overall technical indicators suggest a neutral to positive outlook. With a positive expected return, AMGN appears to be a good long-term investment option. 
